1. Howlader N, Noone A, Krapcho M, Garshell J, Neyman N, et al.. (2013) SEER Cancer Statistics Review (1975–2010). Available: http://seer.cancer.gov/csr/1975_2010/. Accessed 11 June 2014.
2. BarkerLM, PendergrassTW, SandersJE, HawkinsDS (2005) Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol 23: 4354–4362.
3. EsiashviliN, GoodmanM, MarcusRBJr (2008) Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol 30: 425–430.
4. DelattreO, ZucmanJ, MelotT, GarauXS, ZuckerJM, et al. (1994) The Ewing family of tumors–a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 331: 294–299.
5. Turc-CarelC, AuriasA, MugneretF, LizardS, SidanerI, et al. (1988) Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 32: 229–238.
6. SankarS, LessnickSL (2011) Promiscuous partnerships in Ewing's sarcoma. Cancer Genet 204: 351–365.
7. ArmengolG, TarkkanenM, VirolainenM, ForusA, ValleJ, et al. (1997) Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. Br J Cancer 75: 1403–1409.
8. SavolaS, KlamiA, TripathiA, NiiniT, SerraM, et al. (2009) Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer 9: 17.
9. HattingerCM, RumplerS, StrehlS, AmbrosIM, ZoubekA, et al. (1999) Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors. Genes Chromosomes Cancer 24: 243–254.
10. HamelinR, ZucmanJ, MelotT, DelattreO, ThomasG (1994) p53 mutations in human tumors with chimeric EWS/FLI-1 genes. Int J Cancer 57: 336–340.
11. KovarH, AuingerA, JugG, AryeeD, ZoubekA, et al. (1993) Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 8: 2683–2690.
12. KovarH, JugG, AryeeDN, ZoubekA, AmbrosP, et al. (1997) Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 15: 2225–2232.
13. BrownhillSC, TaylorC, BurchillSA (2007) Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT. Br J Cancer 96: 1914–1923.
14. HuangHY, IlleiPB, ZhaoZ, MazumdarM, HuvosAG, et al. (2005) Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 23: 548–558.
15. Lopez-GuerreroJA, PellinA, NogueraR, CardaC, Llombart-BoschA (2001) Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors. Lab Invest 81: 803–814.
16. WeiG, AntonescuCR, de AlavaE, LeungD, HuvosAG, et al. (2000) Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer 89: 793–799.
17. TsuchiyaT, SekineK, HinoharaS, NamikiT, NoboriT, et al. (2000) Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet 120: 91–98.
18. ParkYK, ChiSG, KimYW, ParkHR, UnniKK (2001) P53 mutations in Ewing's sarcoma. Oncol Rep 8: 533–537.
19. KomuroH, HayashiY, KawamuraM, HayashiK, KanekoY, et al. (1993) Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas. Cancer Res 53: 5284–5288.
20. KanZ, JaiswalBS, StinsonJ, JanakiramanV, BhattD, et al. (2010) Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466: 869–873.
21. MolenaarJJ, KosterJ, ZwijnenburgDA, van SluisP, ValentijnLJ, et al. (2012) Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483: 589–593.
22. ShernJF, ChenL, ChmieleckiJ, WeiJS, PatidarR, et al. (2014) Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov 4: 216–231.
23. KnezevichSR, McFaddenDE, TaoW, LimJF, SorensenPH (1998) A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 18: 184–187.
24. RubinBP, ChenCJ, MorganTW, XiaoS, GrierHE, et al. (1998) Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol 153: 1451–1458.
25. TognonC, KnezevichSR, HuntsmanD, RoskelleyCD, MelnykN, et al. (2002) Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2: 367–376.
26. SkalovaA, VanecekT, SimaR, LacoJ, WeinrebI, et al. (2010) Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 34: 599–608.
27. Leeman-NeillRJ, KellyLM, LiuP, BrennerAV, LittleMP, et al. (2013) ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer. Cancer 120: 799–807.
28. ChenQR, VansantG, OadesK, PickeringM, WeiJS, et al. (2007) Diagnosis of the small round blue cell tumors using multiplex polymerase chain reaction. J Mol Diagn 9: 80–88.
29. SolomonDA, KimT, Diaz-MartinezLA, FairJ, ElkahlounAG, et al. (2011) Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 333: 1039–1043.
30. Lopez-GuerreroJA, MachadoI, ScotlandiK, NogueraR, PellinA, et al. (2011) Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's sarcoma family of tumors. Int J Cancer 128: 1139–1150.
31. KatoM, YanoK, MatsuoF, SaitoH, KatagiriT, et al. (2000) Identification of Rad51 alteration in patients with bilateral breast cancer. J Hum Genet 45: 133–137.
32. ZhangJ, BenaventeCA, McEvoyJ, Flores-OteroJ, DingL, et al. (2012) A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481: 329–334.
33. LeeRS, StewartC, CarterSL, AmbrogioL, CibulskisK, et al. (2012) A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest 122: 2983–2988.
34. HasselblattM, IskenS, LingeA, EikmeierK, JeibmannA, et al. (2013) High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors. Genes Chromosomes Cancer 52: 185–190.
35. ChenX, StewartE, ShelatAA, QuC, BahramiA, et al. (2013) Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 24: 710–724.
36. SzuhaiK, IjszengaM, de JongD, KarseladzeA, TankeHJ, et al. (2009) The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin Cancer Res 15: 2259–2268.
37. ItalianoA, SungYS, ZhangL, SingerS, MakiRG, et al. (2012) High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas. Genes Chromosomes Cancer 51: 207–218.
38. BorkhardtA, ReppR, HaasOA, LeisT, HarbottJ, et al. (1997) Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;11)(q13;q23). Oncogene 14: 195–202.
39. BarrFG, QualmanSJ, MacrisMH, MelnykN, LawlorER, et al. (2002) Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res 62: 4704–4710.
40. WalterMJ, ShenD, ShaoJ, DingL, WhiteBS, et al. (2013) Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 27: 1275–1282.
41. SolomonDA, KimJS, BondarukJ, ShariatSF, WangZF, et al. (2013) Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet 45: 1428–1430.
42. KonA, ShihLY, MinaminoM, SanadaM, ShiraishiY, et al. (2013) Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet 45: 1232–1237.
43. Balbas-MartinezC, SagreraA, Carrillo-de-Santa-PauE, EarlJ, MarquezM, et al. (2013) Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet 45: 1464–1469.
44. GuoG, SunX, ChenC, WuS, HuangP, et al. (2013) Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 45: 1459–1463.
45. MazoyerS, DunningAM, SerovaO, DeardenJ, PugetN, et al. (1996) A polymorphic stop codon in BRCA2. Nat Genet 14: 253–254.
46. PlonSE, EcclesDM, EastonD, FoulkesWD, GenuardiM, et al. (2008) Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29: 1282–1291.
47. RuddMF, WebbEL, MatakidouA, SellickGS, WilliamsRD, et al. (2006) Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res 16: 693–701.
48. MartinST, MatsubayashiH, RogersCD, PhilipsJ, CouchFJ, et al. (2005) Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene 24: 3652–3656.
49. AkbariMR, MalekzadehR, NasrollahzadehD, AmanianD, IslamiF, et al. (2008) Germline BRCA2 mutations and the risk of esophageal squamous cell carcinoma. Oncogene 27: 1290–1296.
50. Cancer Genome Atlas Research N (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368: 2059–2074.
51. KimMS, AnCH, YooNJ, LeeSH (2013) Frameshift mutations of chromosome cohesion-related genes SGOL1 and PDS5B in gastric and colorectal cancers with high microsatellite instability. Hum Pathol 44: 2234–2240.
52. CuadradoA, RemeseiroS, Gomez-LopezG, PisanoDG, LosadaA (2012) The specific contributions of cohesin-SA1 to cohesion and gene expression: implications for cancer and development. Cell Cycle 11: 2233–2238.
53. BauerschmidtC, ArrichielloC, Burdak-RothkammS, WoodcockM, HillMA, et al. (2010) Cohesin promotes the repair of ionizing radiation-induced DNA double-strand breaks in replicated chromatin. Nucleic Acids Res 38: 477–487.
54. el-DeiryWS, TokinoT, VelculescuVE, LevyDB, ParsonsR, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817–825.
55. McLellanJL, O'NeilNJ, BarrettI, FerreeE, van PelDM, et al. (2012) Synthetic lethality of cohesins with PARPs and replication fork mediators. PLoS Genet 8: e1002574.
56. GarnettMJ, EdelmanEJ, HeidornSJ, GreenmanCD, DasturA, et al. (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483: 570–575.
57. DrmanacR, SparksAB, CallowMJ, HalpernAL, BurnsNL, et al. (2010) Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 327: 78–81.
58. WangK, LiM, HakonarsonH (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38: e164.
59. KrzywinskiM, ScheinJ, BirolI, ConnorsJ, GascoyneR, et al. (2009) Circos: an information aesthetic for comparative genomics. Genome Res 19: 1639–1645.
60. KimD, SalzbergSL (2011) TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome Biol 12: R72.
61. McPhersonA, HormozdiariF, ZayedA, GiulianyR, HaG, et al. (2011) deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol 7: e1001138.
62. TrapnellC, WilliamsBA, PerteaG, MortazaviA, KwanG, et al. (2010) Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 28: 511–515.